SRD-4610 / Shanghai Pharma - LARVOL DELTA

Shanghai Pharmaceuticals Group Co., Ltd.’s announcement on SRD4610 receiving orphan drug designation from the U.S. FDA [Google translation] (Sina Corp) - "Recently, SRD4610...independently developed by Shanghai SPH Ruier Pharmaceutical Co., Ltd...has been granted Orphan-drug Designation by the U.S. Food and Drug Administration...for the indication of amyotrophic lateral sclerosis (ALS)."

Orphan drug • Amyotrophic Lateral Sclerosis • CNS Disorders